Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors

Environmental and Molecular Mutagenesis

Volumn 48, Issue 3-4, 2007, Pages 215-223

  Olivero, Ofelia A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antiretrovirals; Genotoxicity; Nucleoside analogs

Indexed keywords

CELL NUCLEUS DNA; LAMIVUDINE PLUS ZIDOVUDINE; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; ZIDOVUDINE;

CARCINOGEN DNA INTERACTION; CELL CYCLE S PHASE; CHROMOSOME ABERRATION; DOSE RESPONSE; DRUG DNA BINDING; DRUG MECHANISM; ENZYME INHIBITION; ENZYME REGULATION; GENE; GENE MUTATION; GENOMIC INSTABILITY; GENOTOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HPRT GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERM EXPOSURE; MICRONUCLEUS; NONHUMAN; PERINATAL DRUG EXPOSURE; PHOSPHORYLATION; REVIEW; SISTER CHROMATID EXCHANGE; TK GENE;

ANIMALS; ANTI-HIV AGENTS; CELL CYCLE; DNA; DNA REPAIR; HUMANS; MUTAGENESIS; MUTAGENS; REVERSE TRANSCRIPTASE INHIBITORS; TELOMERASE; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34047221918     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20195     Document Type: Review

References (81)

1. Agarwal RP, Olivero OA. 1997. Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3′-azido-2′,3′- dideoxythymidine (AZT). Mutat Res 390:223-231.
2. Antonelli G, Turriziani O, Verri A, Narciso P, Ferri F, D'Offizi G, Dianzani F. 1996. Long-ter m exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res Hum Retrovir 12:223-228.
3. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. 1991. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337:508-510.
4. Aruna R, Jagetia GC. 2001. Azidothymidine induces dose dependent increase in micronuclei formation in cultured HeLa cells. Pharmazie 56:492-500.
5. Avramis VI, Markson W, Jackson RL, Gomperts E. 1989. Biochemical pharmacology of zidovudine in human T-lymphoblastoid cells (CEM). AIDS 3:417-422.
6. Avramis VI, Kwock R, Solorzano MM, Gomperts E. 1993. Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. J Acquir Immune Defic Syndr 6:1287-1296.
7. Bebenek K, Thomas DC, Roberts JD, Eckstein F, Kunkel TA. 1993. Effects of 3′-azido-3′-deoxythymidine metabolites on simian virus 40 origin-dependent replication and heteroduplex repair in HeLa cell extracts. Mol Pharmacol 43:57-63.
8. Bhalla K, Birkhofer M, Li GR, Grant S, MacLaughlin W, Cole J, Graham G, Volsky DJ. 1989. 2′-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3′-azido-3′- deoxythymidine with preservation of antiretroviral activity. Blood 74:1923-1928.
9. Bialkowska A, Bialkowski K, Gerschenson M, Diwan BA, Jones AB, Olivero OA, Poirier MC, Anderson LM, Kasprzak KS, Sipowicz MA. 2000. Oxidative DNA damage in fetal tissues after transplacental exposure to 3′-azido- 3′-deoxythymidine (AZT). Carcinogenesis 21:1059-1062.
10. Bishop JB, Witt KL, Tice RR, Wolfe GW. 2004. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3′-azido-3′-deoxythymidine and dideoxyinosine via maternal dosing, nursing, and direct gavage. Environ Mol Mutagen 43:3-9.
11. Brunetti I, Falcone A, Calabresi P, Goulette FA, Darnowski JW. 1990. 5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies. Cancer Res 50:4026-4031.
12. Chandrasekaran B, Kute TE, Duch DS. 1995. Synchronization of cells in the S phase of the cell cycle by 3′-azido-3′-deoxythymidine: implications for cell cytotoxicity. Cancer Chemother Pharmacol 35:489-495.
13. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331:1173-1180.
14. Copeland WC, Chen MS, Wang TS. 1992. Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem 267:21459-21464.
15. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. 1990. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322:1098-1105.
16. Darnowski JW, Goulette FA. 1994. 3′-Azido-3′-deoxythymidine cytotoxicity and metabolism In the human colon tumor cell line HCT-8. Biochem Pharmacol 48:1797-1805.
17. de la Asuncion JG, del Olmo ML, Sastre J, Millan A, Pellin A, Pallardo FV, Vina J. 1998. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 102:4-9.
18. de la Asuncion JG, del Olmo ML, Sastre J, Pallardo FV, Vina J. 1999. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology 29:985-987.
19. Dertinger SD, Torous DK, Tometsko KR. 1996. Induction of micronuclei by low doses of azidothymidine (AZT). Mutat Res 368:301-307.
20. Falchetti A, Franchi A, Bordi C, Mavilia C, Masi L, Cioppi F, Recenti R, Picariello L, Marini F, Del Monte F, Ghinoi V, Martineti V, Tanini A, Brandi ML. 2005. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J Bone Miner Res 20:410-418.
21. Fang JL, Beland FA. 2000. Development of a novel (32)P-postlabeling method for the analysis of 3′-azido-3′-deoxythymidine. Cancer Lett 153:25-33.
22. Fridland A, Connelly MC, Ashmun R. 1990. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3′-azido-3′-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol Pharmacol 37:665-670.
23. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, Barry DA. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83:8333-8337.
24. Gomez DE, Kassim A, Olivero OA. 1995. Preferential incorporation of 3′-Azido-2′,3′-dideoxythymidine (AZT) in telomeric sequences of CHO cells. Int J Oncol 7:1057-1060.
25. Gomez DE, Tejera AM, Olivero OA. 1998. Irreversible telomere shortening by 3′-azido-2′, 3′-dideoxythymidine (AZT) treatment. Biochem Biophys Res Commun 246:107-110.
26. Gonzalez CM, Larripa I. 1994. Genotoxicity of azidothymidine (AZT) in in vitro systems. Mutat Res 321:113-118.
27. Han T, Fernandez M, Sarkar M, Agarwal RP. 2004. 2′, 3′-Dideoxycytidine represses thymidine kinases 1 and 2 expression in T-lymphoid cells. Life Sci 74:835-842.
28. Heagy W, Crumpacker C, Lopez PA, Finberg RW. 1991. Inhibition of immune functions by antiviral drugs. J Clin Invest 87:1916-1924.
29. Hoever G, Groeschel B, Chandra P, Doerr HW, Cinatl J. 2003. The mechanism of 3′-azido-2′,3′-dideoxythymidine resistance to human lymphoid cells. Int J Mol Med 11:743-747.
30. Huang P, Farquhar D, Plunkett W. 1990. Selective action of 3′-azido-3′-deoxythymidine 5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem 265:11914-11918.
31. International Agency for Research on Cancer. 2000. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some antiviral and antineoplastic drugs, and other pharmaceutical agents. IARC Monographs 1-521.
32. Jacobsson B, Britton S, He Q, Karlsson A, Eriksson S. 1995. Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. AIDS Res Hum Retrovir 11:805-811.
33. Lee H, Hanes J, Johnson KA. 2003. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42:14711-14719.
34. Lewis W, Simpson JF, Meyer RR. 1994. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 74:344-348.
35. Lim SE, Copeland WC. 2001. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 276:23616-23623.
36. Mamber SW, Brookshire KW, Forenza S. 1990. Induction of the SOS response in Escherichia coli by azidothymidine and dideoxynucleosides. Antimicrob Agents Chemother 34:1237-1243.
37. Melana SM, Holland JF, Pogo BG. 1998. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′- deoxythymidine. Clin Cancer Res 4:693-696.
38. Meng Q, Grosovsky AJ, Shi X, Walker VE. 2000a. Mutagenicity and loss of heterozygosity at the APRT locus in human lymphoblastoid cells exposed to 3′-azido-3′-deoxythymidine. Mutagen 15:405-410.
39. Meng Q, Su T, Olivero OA, Poirier MC, Shi X, Ding X, Walker VE. 200Ob. Relationships between DNA incorporation, mutant frequency, and loss of heterozygosity at the TK locus in human lymphoblastoid cells exposed to 3′-azido-3′-deoxythymidine. Toxicol Sci 54:322-329.
40. Meng Q, Walker DM, Olivero OA, Shi X, Antiochos BB, Poirier MC, Walker VE. 2000c. Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci USA 97:12667-12671.
41. Meng Q, Su T, O'Neill JP, Walker VE. 2002. Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3′-azido-3′-deoxythymidine and 2′,3′- dideoxyinosinedagger. Environ Mol Mutagen 39:282-295.
42. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. 1985. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 82:7096-7100.
43. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL. 2003. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 63:579-585.
44. Multani AS, Furlong C, Pathak S. 1998. Reduction of telomeric signals in murine melanoma and human breast cancer cell lines treated with 3′-azido-2′-3′-dideoxythymidine. Int J Oncol 13:923-925.
45. Murakami J, Nagai N, Shigemasa K, Ohama K. 1999. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur J Cancer 35:1027-1034.
46. Nusbaum NJ, Joseph PE. 1996. AZT incorporation into mitochondria: study in a human myeloid cell line. DNA Cell Biol 15:363-366.
47. Nyce J, Leonard S, Canupp D, Schulz S, Wong S. 1993. Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. Proc Natl Acad Sci USA 90:2960-2964.
48. Olivero OA, Beland FA, Fullerton NF, Poirier MC. 1994a. Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3′-azido-2′,3′- dideoxythymidine (AZT). Cancer Res 54:6235-6242.
49. Olivero OA, Beland FA, Poirier MC. 1994b. Immunofluorescent localization and quantitation of 3′-azido-2′, 3′-dideoxythymidine (AZT) incorporated into chromosomal DNA of human, hamster and mouse cell lines. International Journal of Oncology 4:49-54.
50. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH. Poirier MC. 1997. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 89:1602-1608.
51. Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Landay AL, Baker R, Stek AM, Khoury MM, Proia LA, Kessler HA, Sha BE, Tarone RE, Poirier MC. 1999. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. Aids 13:919-925.
52. Olivero OA, Reddy MK, Pietras SM, Poirier MC. 2001. Plasma drug levels compared with DNA incorporation of 3′-azido-3′-deoxythymidine (AZT) in adult cynomolgus (Macaca fascicularis) monkeys. Exp Biol Med 226:446-449.
53. Olivero OA, Blattner WA, Landay AL, St. Claire M, Poirier MC. 2002. Genotoxicity of Transplacental Nucleoside Analogs (NA) in Primates. Proceedings of the American Association for Cancer Res 43:881.
54. Olivero OA, Das S, Whipkey DL, Weston A, Poirier MC. 2003. Variability in interindividual genotoxic response in normal human mammary epithelial (NHMEC) cells exposed to zidovudine. Environ Mol Mutagen 41:196.
55. Olivero OA, Tejera AM, Fernandez JJ, Taylor BJ, Das S, Divi RL, Poirier MC. 2005. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagen 20:139-146.
56. Panburana P, Sirinavin S, Phuapradit W, Vibhagool A, Chantratita W. 2004. Elective cesarean delivery plus short-course lamivudine and zidovudine for the prevention of mother-to-child transmission of human immunodeficiency virus type 1. Am J Obstet Gynecol 190:803-808.
57. Parker WB, White EL, Shaddix SC, Ross LJ, Buckheit RW, Jr., Germany JM, Secrist JA, III, Vince R, Shannon WM. 1991. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine and 3′-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs. J Biol Chem 266:1754-1762.
58. Phillips MD, Nascimbeni B, Tice RR, Shelby MD. 1991. Induction of micronuclei in mouse bone marrow cells: an evaluation of nucleoside analogues used in the treatment of AIDS. Environ Mol Mutagen 18:168-183.
59. Poirier MC, Olivero OA, Walker DM, Walker VE. 2004. Perinatal genotoxicity and carcinogenity of the antiretroviral nucleoside analog drugs. Toxicol Appl Pharmacol 199:151-161.
60. Pressacco J, Erlichman C. 1993. Combination studies with 3′-azido-3′-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects. Biochem Pharmacol 46:1989-1997.
61. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS. 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 317:192-197.
62. Roskrow M, Wickramasinghe SN. 1990. Acute effects of 3′-azido- 3′-deoxythymidine on the cell cycle of HL60 cells. Clin Lab Haematol 12:177-184.
63. Rylova SN, Albertioni F, Flygh G, Eriksson S. 2005. Activity profiles of deoxynucleoside kinases and 5′-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. Biochem Pharmacol 69:951-960.
64. Sharma M, Jain R, Ionescu E, Darnowski JW. 1995. Quantitative analysis of 3′-azido-3′-deoxythymidine incorporation into DNA in human colon tumor cells. Bioconjug Chem 6:536-540.
65. Skalski V, Liu SH, Cheng YC. 1995. Removal of anti-human immunodeficiency virus 2′,3′-dideoxynucleoside monophosphates from DNA by a novel human cytosolic 3′->5′ exonuclease. Biochem Pharmacol 50:815-821.
66. Sommadossi JP, Carlisle R, Zhou Z. 1989. Cellular pharmacology of 3′-azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol Pharmacol 36:9-14.
67. St.Clair MH, Richards CA, Spector T, Weinhold KJ, Miller WH, Langlois AJ, Furman PA. 1987. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 31:1972-1977.
68. Stern M, Cid MG, Larripa I, Slavutsky I. 1994. AZT-induction of micronuclei in human lymphocyte subpopulations. Toxicol Lett 70:235-242.
69. Strahl C, Blackburn EH. 1994. The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res 22:893-900.
70. Strahl C, Blackburn EH. 1996. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 16:53-65.
71. Sussman HE, Olivero OA, Meng Q, Pietras SM, Poirier MC, O'Neill JP, Finette BA, Bauer MJ, Walker VE. 1999. Genotoxicity of 3′-azido-3′- deoxythymidine in the human lymphoblastoid cell line, TK-6: relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT. Mutat Res 429:249-259.
72. Tornevik Y, Eriksson S. 1990. 2′,3′-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3′-azido-3′-deoxythymidine and thymidine. Mol Pharmacol 38:237-243.
73. Tosi P, Calabresi P, Goulette FA, Renaud CA, Darnowski JW. 1992. Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res 52:4069-4073.
74. Tosi P, Visani G, Ottaviani E, Tura S, Darnowski JW. 1994. Hydroxyurea enhances 3′-azido-3′-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models. Eur J Haematol 52:291-295.
75. Turriziani O, Gianotti N, Bambacioni F, Manconi PE, Lazzarin A, Antonelli G. 2004. Lack of reduction of thymidine kinase activity in stavudine-treated HIV-infected patients. AIDS Res Hum Retrovir 20:701-703.
76. Vazquez-Padua MA, Starnes MC, Cheng YC. 1990. Incorporation of 3′-azido-3′-deoxythymidine into cellular DNA, its removal in a human leukemic cell line. Cancer Commun 2:55-62.
77. Viora M, Di Genova G, Rivabene R, Malorni W, Fattorossi A. 1997. Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs. Int J Immunopharmacol 19:311-321.
78. Witt KL, Tice RR, Wolfe GW, Bishop JB. 2004. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3′-azido-3′-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment. Environ Mol Mutagen 44:321-328.
79. Wu S, Liu X, Solorzano MM, Kwock R, Avramis VI. 1995. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5′ end of human TK gene. J Acquir Immune Defic Syndr Hum Retrovirol 8:1-9.
80. Wu YW, Xiao Q, Jiang YY, Fu H, Ju Y, Zhao YF. 2004. Synthesis, in vitro anticancer evaluation, and interference with cell cycle progression of N-phosphoamino acid esters of zidovudine and stavudine. Nucleosides Nucleotides Nucleic Acids 23:1797-1811.
81. Yegorov YE, Chernov DN, Akimov SS, Akhmalisheva AK, Smirnova YB, Shinkarev DB, Semenova IV, Yegorova IN, Zelenin AV. 1997. Blockade of telomerase function by nucleoside analogs. Biochemistry (Mosc) 62:1296-1305.